Incyte’s CCR5 Antagonist Has “Meaningful Advantages” Over Pfizer’s Maraviroc, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Company says it is in active licensing discussions with “probably half a dozen” firms.
You may also be interested in...
Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound
Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.
Incyte Will First Seek Myelofibrosis, Rheumatoid Arthritis Indications For Lead JAK Compound
Oral Janus associated kinase inhibitor '424 may prove superior to currently approved anti-TNF agents and Roche’s IL-6 inhibitor Actemra for RA, Incyte CEO says.
Schering-Plough, Incyte Report Positive Mid-Stage Data For CCR5 Antagonists
Both Schering’s vicriviroc and Incyte’s INCB9471 CCR5 antagonist candidates to treat HIV beat placebo in Phase II trials.